Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating Primary Liver Cancer.
10.1007/s11655-021-3449-8
- Author:
Zhen ZHANG
1
;
Jun-Wei LI
2
,
3
;
Pu-Hua ZENG
4
;
Wen-Hui GAO
5
;
Xue-Fei TIAN
6
Author Information
1. Department of Internal Medicine, College of Integrated Chinese and Western Medicine of Hunan University of Chinese Medicine, Changsha, 410208, China.
2. Department of Pharmacy, Shenzhen People's Hospital (the Second Clinical Medical College, Jinan University
3. the First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong Province, 518020, China.
4. Department of Oncology, Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha, 410006, China.
5. Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China.
6. Department of Internal Medicine, College of Integrated Chinese and Western Medicine of Hunan University of Chinese Medicine, Changsha, 410208, China. 003640@hnucm.edu.cn.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
bioinformatics;
primary liver cancer;
system pharmacology;
tumor microenvironment
- MeSH:
Data Mining;
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Liver Neoplasms/drug therapy*;
Medicine, Chinese Traditional;
Network Pharmacology;
Retrospective Studies;
Tumor Microenvironment
- From:
Chinese journal of integrative medicine
2022;28(7):636-643
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To identify specific Chinese medicines (CM) that may benefit patients with primary liver cancer (PLC), and to explore the mechanism of action of these medicines.
METHODS:In this retrospective, singlecenter study, prescription information from PLC patients was used in combination with Traditional Chinese Medicine Inheritance Supports System to identify the specific core drugs. A system pharmacology approach was employed to explore the mechanism of action of these medicines.
RESULTS:Taking CM more than 6 months was significantly associated with improved survival outcomes. In total, 77 putative targets and 116 bioactive ingredients of the core drugs were identified and included in the analysis (P<0.05). A total of 1,036 gene ontology terms were found to be enriched in PLC. A total of 75 pathways identified from Kyoto Encyclopedia of Genes and Genomes were also enriched in this disease, including fluid shear stress, interleukin-17 signaling, signaling between advanced glycan end products and their receptors, cellular senescence, tumor necrosis factor signaling, p53 signaling, cell cycle signaling, steroid hormone biosynthesis, T-helper 17 cell differentiation, and metabolism of xenobiotics by cytochrome. Docking studies suggested that the ingredients in the core drugs exert therapeutic effects in PLC by modulating c-Jun and interleukin-6.
CONCLUSIONS:Receiving CM for 6 months or more improves survival for the patients with PLC. The core drugs that really benefit for PLC patients likely regulates the tumor microenvironment and tumor itself.
